Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Astal Laboratories Ltd filed its quarterly Statement of Deviation and Variation for the quarter ended March 31, 2026. The company reported two fund-raising events: (1) A preferential issue on January 14, 2026 where Rs. 0 was raised as this was a share swap arrangement for acquiring 100% equity of Sriven Pharmachem India Private Limited through issuance of equity shares at Rs. 91 per share in 1:1 ratio, and (2) A rights issue on the same date raising Rs. 306 lakhs for capital expenditure, working capital and general corporate purposes. Out of the Rs. 306 lakhs raised, Rs. 286 lakhs (93.5%) has been utilized so far. The Audit Committee reviewed both statements and confirmed no deviation or variation in the use of funds for either event.
The filing indicates normal fund deployment with no irregularities. The high utilization rate (93.5%) and zero deviation suggest the company is progressing as planned on its capital deployment. The acquisition of Sriven Pharmachem was completed without cash outflows via share swap, which is dilutive but non-cash for existing shareholders.